Quick Answer
CollPlant Biotechnologies Ltd reported Cash and Equivalents of $5.59 million for fiscal year 2025.
CollPlant Biotechnologies Ltd Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $5.59M | -53.1% |
| 2024 | $11.91M | -55.4% |
| 2023 | $26.67M | -10.0% |
| 2022 | $29.65M | +125.5% |
| 2021 | $13.15M | +294.5% |
| 2020 | $3.33M | -12.1% |
| 2019 | $3.79M | -29.2% |
| 2018 | $5.35M | — |
- CollPlant Biotechnologies Ltd showed a decrease of -53.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, CollPlant Biotechnologies Ltd’s cash and equivalents has grown by 4.4% (from $5.35 million to $5.59 million).
- The most recent figure is from CollPlant Biotechnologies Ltd’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: